Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration

NCT07088445 is registered in ClinicalTrials.gov with Hui Peng as lead sponsor.

NCT NCT07088445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07088445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
Lead sponsor
Hui Peng
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
June 30, 2026
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration(namd)